Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014231 · ClinicalTrials.gov registry record
Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer
A clinical trial of Malignant Neoplasm, sponsored by City of Hope Medical Center.
- Active
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT04014231 is a study of Malignant Neoplasm that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 160 participants, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04014231, a study of Malignant Neoplasm, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies a novel single wave assessment in measuring cardiac dysfunction and metabolic syndrome in patients with cancer. The novel single wave assessment is a hand held device that can report left ventricular ejection fraction, which measures how well the heart is pumping blood (by giving a percentage) and measures how stiff the arteries are in the heart (pulse wave velocity). A novel single wave assessment may help identify patients at increased risk for type II diabetes and metabolic syndrome (disease where patients have increased blood pressure and high blood sugar level and excess body fat around the waist and abnormal cholesterol levels).
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Diagnostic Imaging
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2026-05-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04014231
The ClinicalTrials.gov registry entry for NCT04014231 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (69% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT04014231 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04014231 about?
NCT04014231 is a clinical study titled "Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer". This clinical trial studies a novel single wave assessment in measuring cardiac dysfunction and metabolic syndrome in patients with cancer. The novel single wave assessment is a hand held device that can report left ventricular ejection fraction, which measures how well the heart is pumping blood (b...
What is the current status of trial NCT04014231?
This trial is currently active not recruiting. The enrollment target is 160 participants. The study started on 2017-07-21. Estimated completion is 2026-05-11.
What conditions does trial NCT04014231 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT04014231?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Diagnostic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT04014231?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04014231 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.